{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:08Z","timestamp":1790736668231,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"X4 Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in CXCR4 C-terminus. We assessed genotype\u2013phenotype correlations for known pathogenic CXCR4 variants and in vitro response of each variant to mavorixafor, an investigational CXCR4 antagonist. We used cell-based assays to analyze CXCL12-induced receptor trafficking and downstream signaling of 14 pathogenic CXCR4 variants previously identified in patients with WHIM syndrome. All CXCR4 variants displayed impaired receptor trafficking, hyperactive downstream signaling, and enhanced chemotaxis in response to CXCL12. Mavorixafor inhibited CXCL12-dependent signaling and hyperactivation in cells harboring CXCR4<jats:sup>WHIM<\/jats:sup>mutations. A strong correlation was found between CXCR4 internalization defect and severity of blood leukocytopenias and infection susceptibility, and between AKT activation and immunoglobulin A level and CD4<jats:sup>+<\/jats:sup>T-cell counts. This study is the first to show WHIM syndrome clinical phenotype variability as a function of both<jats:italic>CXCR4<\/jats:italic><jats:sup>WHIM<\/jats:sup>genotype diversity and associated functional dysregulation. Our findings suggest that CXCR4 internalization may be used to assess the pathogenicity of<jats:italic>CXCR4<\/jats:italic>variants in vitro and also as a potential WHIM-related disease biomarker. The investigational CXCR4 antagonist mavorixafor inhibited CXCL12-dependent signaling in all tested CXCR4-variant cell lines at clinically relevant concentrations.<\/jats:p>","DOI":"10.1038\/s41435-022-00181-9","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:02:43Z","timestamp":1662948163000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Genotype\u2013phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4WHIM variants"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-7039","authenticated-orcid":false,"given":"Katarina","family":"Zmajkovicova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Maier-Munsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Maierhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Skerlj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur G.","family":"Taveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Badarau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"181_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0002-9343(90)90187-I","volume":"89","author":"M Wetzler","year":"1990","unstructured":"Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med. 1990;89:663\u201372.","journal-title":"Am J Med"},{"key":"181_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMoa1808575","volume":"380","author":"DH McDermott","year":"2019","unstructured":"McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380:163\u201370.","journal-title":"N Engl J Med"},{"key":"181_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-71","volume":"7","author":"S Beaussant Cohen","year":"2012","unstructured":"Beaussant Cohen S, Fenneteau O, Plouvier E, Rohrlich P-S, Daltroff G, Plantier I, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71.","journal-title":"Orphanet J Rare Dis"},{"key":"181_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1600-0609.2006.00779.x","volume":"78","author":"K Alapi","year":"2007","unstructured":"Alapi K, Erdos M, Kov\u00e1cs G, Mar\u00f3di L. Recurrent CXCR4 sequence variation in a girl with WHIM syndrome. Eur J Haematol. 2007;78:86\u20138.","journal-title":"Eur J Haematol"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2004-06-2289","volume":"105","author":"K Balabanian","year":"2005","unstructured":"Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105:2449\u201357.","journal-title":"Blood."},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/blood-2003-10-3532","volume":"104","author":"AV Gulino","year":"2004","unstructured":"Gulino AV, Moratto D, Sozzani S, Cavadini P, Otero K, Tassone L, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood. 2004;104:444\u201352.","journal-title":"Blood."},{"key":"181_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ng1149","volume":"34","author":"PA Hernandez","year":"2003","unstructured":"Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34:70\u20134.","journal-title":"Nat Genet"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood-2011-12-395608","volume":"120","author":"Q Liu","year":"2012","unstructured":"Liu Q, Chen H, Ojode T, Gao X, Anaya-O\u2019Brien S, Turner NA, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood. 2012;120:181\u20139.","journal-title":"Blood."},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10875-016-0276-3","volume":"36","author":"Q Liu","year":"2016","unstructured":"Liu Q, Pan C, Lopez L, Gao J, Velez D, Anaya-O\u2019Brien S, et al. WHIM syndrome caused by Waldenstr\u00f6m\u2019s macroglobulinemia-associated mutation CXCR4 L329fs. J Clin Immunol. 2016;36:397\u2013405.","journal-title":"J Clin Immunol"},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jaci.2016.04.057","volume":"138","author":"L Moens","year":"2016","unstructured":"Moens L, Frans G, Bosch B, Bossuyt X, Verbinnen B, Poppe W, et al. Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome. J Allergy Clin Immunol. 2016;138:1485\u20139.e2.","journal-title":"J Allergy Clin Immunol"},{"key":"181_CR11","doi-asserted-by":"crossref","unstructured":"Tassone L, Notarangelo LD, Bonomi V, Savoldi G, Sensi A, Soresina A, et al. Clinical and genetic diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome in 10 patients. J Allergy Clin Immunol. 2009;123:1170\u20133.","DOI":"10.1016\/j.jaci.2008.12.1133"},{"key":"181_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21165696","volume":"21","author":"S Milanesi","year":"2020","unstructured":"Milanesi S, Locati M, Borroni EM. Aberrant CXCR4 signaling at crossroad of WHIM syndrome and Waldenstrom\u2019s macroglobulinemia. Int J Mol Sci. 2020;21:1\u201315.","journal-title":"Int J Mol Sci"},{"key":"181_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.16088","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187:356\u201363.","journal-title":"Br J Haematol"},{"key":"181_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ajh.26339","volume":"96","author":"D Krzisch","year":"2021","unstructured":"Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F, et al. Cytogenetic and molecular abnormalities in Waldenstrom\u2019s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol. 2021;96:1569\u201379.","journal-title":"Am J Hematol"},{"key":"181_CR15","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood.2020007197","volume":"136","author":"DC Dale","year":"2020","unstructured":"Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136:2994\u20133003.","journal-title":"Blood."},{"key":"181_CR16","doi-asserted-by":"crossref","unstructured":"Schoofs G, Van Hout A, D\u2019Huys T, Schols D, Van Loy T. A flow cytometry-based assay to identify compounds that disrupt binding of fluorescently-labeled CXC chemokine ligand 12 to CXC chemokine receptor 4. J Vis Exp. 2018;10:57271.","DOI":"10.3791\/57271"},{"key":"181_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2007-07-102103","volume":"112","author":"B Lagane","year":"2008","unstructured":"Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T, et al. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008;112:34\u201344.","journal-title":"Blood"},{"key":"181_CR18","doi-asserted-by":"crossref","unstructured":"Luo J, De Pascali F, Richmond GW, Khojah AM, Benovic JL. Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4. J Biol Chem. 2022;298:101551.","DOI":"10.1016\/j.jbc.2021.101551"},{"key":"181_CR19","unstructured":"Gernez Y, Chavez C, Bussel J, Cunningham-Rundles C. Unexpecteddiagnosis in a family with autoimmune multilineage cytopenia and hypogammaglobulinemia. J Clin Immunol. 2019;39:1."},{"key":"181_CR20","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jaip.2019.01.045","volume":"7","author":"L Dotta","year":"2019","unstructured":"Dotta L, Notarangelo LD, Moratto D, Kumar R, Porta F, Soresina A, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol Pract. 2019;7:1568\u201377.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"181_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00043426-199709000-00007","volume":"19","author":"JD Hord","year":"1997","unstructured":"Hord JD, Whitlock JA, Gay JC, Lukens JN. Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature. J Pediatr Hematol Oncol. 1997;19:443\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"181_CR22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1111\/j.1582-4934.2010.01210.x","volume":"15","author":"DH Mcdermott","year":"2011","unstructured":"Mcdermott DH, Lopez J, Deng F, Liu Q, Ojode T, Chen H, et al. AMD3100 is a potent antagonist at CXCR4 R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mod Med 2011;15:2071\u201381.","journal-title":"J Cell Mod Med"},{"key":"181_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2567.2002.01345.x","volume":"105","author":"AP Curnock","year":"2002","unstructured":"Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology. 2002;105:125\u201336.","journal-title":"Immunology."},{"key":"181_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s10875-019-00665-w","volume":"39","author":"LE Heusinkveld","year":"2019","unstructured":"Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39:532\u201356.","journal-title":"J Clin Immunol"},{"key":"181_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12860-021-00347-9","volume":"22","author":"L Wang","year":"2021","unstructured":"Wang L, Xiong Q, Li P, Chen G, Tariq N, Wu C. The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4. BMC Mol Cell Biol. 2021;22:8.","journal-title":"BMC Mol Cell Biol."},{"key":"181_CR26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4049\/jimmunol.160.2.877","volume":"160","author":"J Hesselgesser","year":"1998","unstructured":"Hesselgesser J, Liang M, Hoxie J, Greenberg M, Brass LF, Orsini MJ, et al. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol. 1998;160:877\u201383.","journal-title":"J Immunol"},{"key":"181_CR27","doi-asserted-by":"publisher","first-page":"45509","DOI":"10.1074\/jbc.C100527200","volume":"276","author":"A Marchese","year":"2001","unstructured":"Marchese A, Benovic JL. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem. 2001;276:45509\u201312.","journal-title":"J Biol Chem"},{"key":"181_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bcp.2011.11.020","volume":"83","author":"RM Mosi","year":"2012","unstructured":"Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, et al. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 2012;83:472\u20139.","journal-title":"Biochem Pharmacol"},{"key":"181_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","volume":"7","author":"A Singh","year":"2020","unstructured":"Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). Genes Dis. 2020;7:67\u201374.","journal-title":"Genes Dis"},{"key":"181_CR30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/ATVBAHA.106.132282","volume":"27","author":"MJ Lorenowicz","year":"2007","unstructured":"Lorenowicz MJ, Fernandez-Borja M, Hordijk PL. cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc. 2007;27:1014\u201322.","journal-title":"Arterioscler Thromb Vasc"},{"key":"181_CR31","doi-asserted-by":"crossref","unstructured":"Mueller W, Sch\u00fctz D, Nagel F, Schulz S, Stumm R. Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS ONE. 2013;8:e64975.","DOI":"10.1371\/journal.pone.0064975"},{"key":"181_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1534-5807(03)00321-6","volume":"5","author":"A Marchese","year":"2003","unstructured":"Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell. 2003;5:709\u201322.","journal-title":"Dev Cell"},{"key":"181_CR33","doi-asserted-by":"crossref","unstructured":"Cronshaw DG, Nie Y, Waite J, Zou YR. An essential role of the cytoplasmic tail of CXCR4 in G-protein signaling and organogenesis. PLoS ONE. 2010;5.e15397.","DOI":"10.1371\/journal.pone.0015397"},{"key":"181_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.12574","volume":"164","author":"O Al Ustwani","year":"2014","unstructured":"Al Ustwani O, Kurzrock R, Wetzler M. Genetics on a WHIM. Br J Haematol. 2014;164:15\u201323.","journal-title":"Br J Haematol"},{"key":"181_CR35","doi-asserted-by":"publisher","first-page":"eaay5024","DOI":"10.1126\/scisignal.aay5024","volume":"13","author":"BS Stephens","year":"2020","unstructured":"Stephens BS, Ngo T, Kufareva I, Handel TM. Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis. Sci Signal. 2020;13:eaay5024.","journal-title":"Sci Signal"},{"key":"181_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1124\/jpet.116.239665","volume":"362","author":"J Gatfield","year":"2017","unstructured":"Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, et al. Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low \u03b2-arrestin recruitment and desensitization potential. J Pharmacol Exp Ther. 2017;362:186\u201399.","journal-title":"J Pharmacol Exp Ther"},{"key":"181_CR37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.108.049775","volume":"74","author":"RS Wong","year":"2008","unstructured":"Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol. 2008;74:1485\u201395.","journal-title":"Mol Pharmacol"}],"container-title":["Genes &amp; Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-022-00181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-022-00181-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-022-00181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T18:53:21Z","timestamp":1676746401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-022-00181-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1038\/s41435-022-00181-9","relation":{},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X4 Pharmaceuticals funded the development of this paper. KZ, SP, SM, BM, IW, and AT are employees and KZ, SP, SM, BM, IW, and AT hold shares of X4 Pharmaceuticals, a clinical-stage company developing small molecule CXCR4 antagonists for the treatment of WHIM syndrome, WM, and other diseases. SP, RS, and AB were employees of X4 at the time of writing and are now former employees who hold shares in X4.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}